Banksy made a name for himself in the early 1990s when he started spray-painting stencils around Bristol ... a Broken Heart” is a 6-foot-by-9-foot, 7500-pound chunk of the wall where the ...

This Father’s Day, show your dad you care with more than a card and a bar of chocolate – treat him to one of the nation’s ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Auburn baseball battled back against Coastal Carolina but came up short in extra innings in Game One of super regional ...

A popular international travel blog recently chose Bristol as the best small town ... the true authentic heart of America and the influences of old European settlers is waiting to be explored.

Researchers have developed an in-home foot scanner that utilises artificial intelligence (AI) to detect early signs of heart failure ... is designed to be wall-mounted near the patient's bed.

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its experimental heart drug delayed by an extra three months over an unusual ...

A young Bristol woman is planning to run the London Marathon in aid of her "admirable" brother, who suffers with a congenital heart defect. Elena Morris, 22, from Bradley Stoke aims to complete ...

In its upcoming report, Bristol Myers Squibb (BMY) is predicted by Wall Street analysts to post quarterly earnings of $1.54 per share, reflecting an increase of 135% compared to the same period ...

Bristol Myers Squibb on Monday said its drug Camzyos failed a Phase 3 trial in people with a progressive heart condition, closing off an opportunity to expand use of a medicine it sees as a future ...

(RTTNews) - Bristol Myers Squibb (BMY) announced that the Phase 3 ODYSSEY-HCM trial, which evaluated Camzyos or mavacamten for the treatment of adult patients with symptomatic New York Heart ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE ... the drug's efficacy in adult patients with symptomatic New York Heart Association (NYHA) class II-III nHCM. The trial, which enrolled 580 adults ...